BAMS
CYTO

Bellevue Asset Management (Switzerland)’s Altamira Therapeutics Ltd CYTO Stock Holding History

Bellevue Asset Management (Switzerland)’s Portfolio CYTO Stock Details CYTO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		$10.4M Hold
27
– – 1.59% 17
2015
Q3 		$7.72M Hold
27
– – 1.26% 24
2015
Q2 		$10.7M Hold
27
– – 1.49% 18
2015
Q1 		$11.6M Buy
+27
New +$10.9M 1.62% 14

Other funds holding CYTO

WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
CPCM
Clifton Park Capital Management Wilmington, Delaware $881M AUM 5.59% 1-Year Est. Return
TCM
Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
TAM
Tocqueville Asset Management New York $6.74B AUM 32.29% 1-Year Est. Return
HCM
Harvey Capital Management Palm Beach, Florida $439M AUM 37.68% 1-Year Est. Return
KeyBank National Association
KeyBank National Association Cleveland, Ohio $30.4B AUM 27.51% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Bellevue Asset Management (Switzerland)'s CYTO Position: Q4 2015 in Review

Bellevue Asset Management (Switzerland) held its Altamira Therapeutics Ltd (CYTO) position steady in Q4 2015 at 27 shares worth $10.4M. The position accounts for 1.59% of the portfolio, ranked #17.

Bellevue Asset Management (Switzerland) first reported a position in CYTO in Q1 2015 and has held it in 4 quarters since. The position peaked at $11.6M in Q1 2015. 10 funds tracked by Wall St. Rank hold CYTO as of Q4 2015.

  • Bellevue Asset Management (Switzerland) held 27 shares of Altamira Therapeutics Ltd worth $10.4M as of Q4 2015.
  • Bellevue Asset Management (Switzerland) left its Altamira Therapeutics Ltd share count unchanged in Q4 2015.
  • Altamira Therapeutics Ltd made up 1.59% of Bellevue Asset Management (Switzerland)'s portfolio in Q4 2015, its #17 holding.
  • Bellevue Asset Management (Switzerland) first reported a position in Altamira Therapeutics Ltd in Q1 2015 and has held it in 4 quarters since.
  • Bellevue Asset Management (Switzerland)'s Altamira Therapeutics Ltd position peaked at $11.6M in Q1 2015.
  • 10 funds tracked by Wall St. Rank held Altamira Therapeutics Ltd as of Q4 2015.

Based on Bellevue Asset Management (Switzerland)'s 13F filing for Q4 2015, filed 12 Feb 2016.